174 related articles for article (PubMed ID: 20957741)
21. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
Modesitt SC; Parsons SJ
Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
[TBL] [Abstract][Full Text] [Related]
23. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
[TBL] [Abstract][Full Text] [Related]
24. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.
Baschnagel A; Russo A; Burgan WE; Carter D; Beam K; Palmieri D; Steeg PS; Tofilon P; Camphausen K
Mol Cancer Ther; 2009 Jun; 8(6):1589-95. PubMed ID: 19509253
[TBL] [Abstract][Full Text] [Related]
25. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
[TBL] [Abstract][Full Text] [Related]
26. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
27. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
Duvic M; Dimopoulos M
Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
[TBL] [Abstract][Full Text] [Related]
28. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
[TBL] [Abstract][Full Text] [Related]
29. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
[TBL] [Abstract][Full Text] [Related]
30. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
31. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.
Wilson PM; Labonte MJ; Martin SC; Kuwahara ST; El-Khoueiry A; Lenz HJ; Ladner RD
Invest New Drugs; 2013 Aug; 31(4):845-57. PubMed ID: 23299388
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
Hui KF; Lam BH; Ho DN; Tsao SW; Chiang AK
Mol Cancer Ther; 2013 May; 12(5):747-58. PubMed ID: 23475956
[TBL] [Abstract][Full Text] [Related]
33. Development of a histone deacetylase 6 inhibitor and its biological effects.
Lee JH; Mahendran A; Yao Y; Ngo L; Venta-Perez G; Choy ML; Kim N; Ham WS; Breslow R; Marks PA
Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15704-9. PubMed ID: 24023063
[TBL] [Abstract][Full Text] [Related]
34. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
Phillip CJ; Giardina CK; Bilir B; Cutler DJ; Lai YH; Kucuk O; Moreno CS
BMC Cancer; 2012 Apr; 12():145. PubMed ID: 22494660
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer.
Lin WH; Yeh TK; Jiaang WT; Yen KJ; Chen CH; Huang CT; Yen SC; Hsieh SY; Chou LH; Chen CP; Chiu CH; Kao LC; Chao YS; Chen CT; Hsu JT
PLoS One; 2014; 9(1):e83160. PubMed ID: 24416160
[TBL] [Abstract][Full Text] [Related]
36. Antioxidants impair anti-tumoral effects of Vorinostat, but not anti-neoplastic effects of Vorinostat and caspase-8 downregulation.
Bergadà L; Yeramian A; Sorolla A; Matias-Guiu X; Dolcet X
PLoS One; 2014; 9(3):e92764. PubMed ID: 24651472
[TBL] [Abstract][Full Text] [Related]
37. Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells.
Eto S; Saeki K; Yoshitake R; Yoshimoto S; Shinada M; Ikeda N; Kamoto S; Tanaka Y; Kato D; Maeda S; Tsuboi M; Chambers J; Uchida K; Nishimura R; Nakagawa T
PLoS One; 2019; 14(6):e0218382. PubMed ID: 31206526
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and anticancer activity of novel histone deacetylase inhibitors that inhibit autophagy and induce apoptosis.
Mo H; Zhang R; Chen Y; Li S; Wang Y; Zou W; Lin Q; Zhao DG; Du Y; Zhang K; Ma YY
Eur J Med Chem; 2022 Dec; 243():114705. PubMed ID: 36215854
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
Lee JH; Choy ML; Ngo L; Foster SS; Marks PA
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14639-44. PubMed ID: 20679231
[TBL] [Abstract][Full Text] [Related]
40. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
